



## **Hikma wins Mitigare / Colchicine patent infringement case**

**London, 19 May 2016** – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, today announces that the United States District Court for the District of Delaware has ruled in favour of Hikma and its wholly-owned subsidiary in the United States, West-Ward Pharmaceutical Corp., by granting their motion to dismiss claims made by Takeda Pharmaceuticals USA, Inc. for alleged infringement of patents covering methods of use of Takeda's colchicine product, Colcrys®.

Since January 2015, Hikma has been marketing its own colchicine product under the brand name Mitigare™, as well as selling an authorised generic, increasing patient access to this important product in the United States.

Said Darwazah, Chairman and CEO of Hikma, said:

"I am very pleased with the ruling of the Delaware Court. This is a successful outcome and demonstrates our commitment to bringing more differentiated products to the US market."

-- ENDS --

### **Enquiries**

#### **Hikma Pharmaceuticals PLC**

Susan Ringdal, VP Corporate Strategy and Investor Relations  
Zeena Murad, Investor Relations Manager

+44 (0)20 7399 2760/ +44 7776 477050  
+44 (0) 20 7399 2768/ +44 7771 665277

#### **FTI Consulting**

Ben Atwell/ Matthew Cole / Julia Phillips

+44 (0)20 3727 1000

### **About Hikma**

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Injectables", "Branded" and "Generics", based principally in the United States, the Middle East and North Africa (MENA) and Europe. In 2015, Hikma achieved revenues of \$1,440 million and profit attributable to shareholders of \$252 million.